- Wogonoside
-
- $45.00 / 5mg
-
2025-05-27
- CAS:51059-44-0
- Min. Order:
- Purity: 98.24%
- Supply Ability: 10g
- Wogonoside
-
- $0.00 / 20mg
-
2023-02-24
- CAS:51059-44-0
- Min. Order: 5mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
|
| | BETA-D-GLUCOPYRANOSIDURONIC ACID Basic information |
| | BETA-D-GLUCOPYRANOSIDURONIC ACID Chemical Properties |
| Melting point | 226-227℃ | | Boiling point | 820.7±65.0 °C(Predicted) | | density | 1.629 | | storage temp. | -20°C | | solubility | DMSO (Slightly), Methanol (Very Slightly) | | form | Solid | | pka | 2.73±0.70(Predicted) | | color | Pale Yellow | | InChIKey | LNOHXHDWGCMVCO-NTKSAMNMSA-N |
| Hazard Codes | Xn | | Risk Statements | 22 | | WGK Germany | 3 | | HS Code | 2938.90.0000 |
| | BETA-D-GLUCOPYRANOSIDURONIC ACID Usage And Synthesis |
| Uses | Wogonoside is a flavonoid present in extracts from plant Radic scutellariae and provides antioxidant activity. | | Definition | ChEBI: The glycosyloxyflavone which is the 7-O-glucuronide of wogonin. | | General Description | Natural product derived from plant source. | | Biochem/physiol Actions | Wogonoside, a flavanoid, is known for its anti-inflammatory properties. Wogonoside may have therapeutic potential for use in diseases which involve the development of inflammation and angiogenesis through its inhibition of LPS-induced angiogenesis. | | in vivo | Wogonoside (80 mg/kg, oral gavage, once every other day) inhibits tumor growth and metastasis in MDA-MB-231 orthotopic model[3].
Wogonoside (40 or 80 mg/kg, i.p., every three days) inhibits tumor growth and reduces Bcl-2/Bax ratio in A549 cell xenograft mice[4].
Wogonoside (80 mg/kg, i.P., every other day for 14 days) also inhibits tumor growth in U937 xenograft model[5].
| Animal Model: | MDA-MB-231 orthotopic model[3] | | Dosage: | 80 mg/kg | | Administration: | oral gavage, once every other day | | Result: | Inhibited tumor growth (46%) and metastasis in brain, lung, liver and bone.
Increased the expression of E-cadherin and reduced the expression of MMP-9, vimentin and Twist1 at ?orthotopic site. |
|
| | BETA-D-GLUCOPYRANOSIDURONIC ACID Preparation Products And Raw materials |
|